Colorectal Cancer Clinical Trials in Los Angeles

Showing 41-60 of 218 trials

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

NCT05360680

This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitumor activity of CUE-102 intravenous (IV) monotherapy in HLA-A\*0201 positive patients with WT1 positive recurrent/metastatic solid tumors who have failed conventional therapies.

Colorectal CancerGastric CancerPancreatic Cancer+1 more

Cue Biopharma42 participantsStarted Jun 2022

Phoenix, Arizona, United States • Los Angeles, California, United States • Palo Alto, California, United States +12 more locations

RECRUITINGPhase 1/2< 1 mile

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

NCT06428409

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: * About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it * How many people have the cancer respond (get smaller or go away) to treatment

Colorectal CancerPancreatic Ductal AdenocarcinomaBiliary Tract Cancer

Merck Sharp & Dohme LLC220 participantsStarted Jun 2024

Los Angeles, California, United States • Aurora, Colorado, United States • Aurora, Colorado, United States +52 more locations

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Colorectal Cancer Trials in Other Cities

EXoPERT EMERALD Clinical Study

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Community Collaboration to Advance Racial/Ethnic Equity in CRC Screening

Prevention of Colorectal Cancer Through Multiomics Blood Testing

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Medical and Psychosocial Issues in Adolescents and Young Adults With Colorectal Cancer

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

Other Conditions in Los Angeles